









Markets
/
Stocks
/
nasdaq-lpcn
/

Lipocine Inc

LPCN

8.490USD

+0.770+9.97%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

46.02MMarket Cap

LossP/E TTM



Lipocine Inc

8.490

+0.770+9.97%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lipocine Inc

Currency: USD Updated: 2026-02-06

Key Insights

Lipocine Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 109 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.88.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lipocine Inc's Score

Industry at a Glance

Industry Ranking

109 / 392

Overall Ranking

239 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lipocine Inc Highlights

StrengthsRisks

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2139.63% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.20M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -8.35, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.04M shares, increasing 31.59% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 36.10K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.46.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.875

Target Price

+40.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Lipocine Inc is 7.45, ranking 108 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.45

Change



Financials

8.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.01

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.09

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.48

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lipocine Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Lipocine Inc is 7.33, ranking 137 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.35, which is -40725.19% below the recent high of 3391.03 and -32.63% above the recent low of -11.07.

Score

Industry at a Glance

Previous score

7.33

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Lipocine Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.88, with a high of 7.00 and a low of 6.75.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.875

Target Price

+40.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Lipocine Inc

LPCN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Lipocine Inc is 7.03, ranking 115 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.45 and the support level at 6.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.895

Neutral

RSI(14)

50.660

Neutral

STOCH(KDJ)(9,3,3)

15.522

Neutral

ATR(14)

0.947

Low Volatility

CCI(14)

-81.085

Neutral

Williams %R

75.036

Sell

TRIX(12,20)

1.010

Sell

StochRSI(14)

62.799

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

8.350

Buy

MA10

9.029

Sell

MA20

9.608

Sell

MA50

6.603

Buy

MA100

4.762

Buy

MA200

3.975

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Lipocine Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.66%, representing a quarter-over-quarter increase of 96.08%. The largest institutional shareholder is The Vanguard, holding a total of 221.87K shares, representing 4.00% of shares outstanding, with 5.51% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Squadron Capital Management LLC

500.00K

The Vanguard Group, Inc.

Star Investors

221.87K

-1.34%

Patel (Mahesh V)

109.05K

+1.52%

BlackRock Institutional Trust Company, N.A.

89.27K

Geode Capital Management, L.L.C.

61.08K

Susquehanna International Group, LLP

46.76K

+1.61%

Higuchi (John W)

40.80K

Renaissance Technologies LLC

Star Investors

36.10K

+3.74%

State Street Investment Management (US)

18.63K

Citadel Advisors LLC

14.25K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lipocine Inc is 2.66, ranking 213 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.